Sector: MedicalAnadys Pharmaceuticals, Inc. (NASDAQ: ANDS)
Headlines
- Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
Oct 29, 2009 04:06 PM | ANDS
- Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Oct 28, 2009 04:05 PM | ANDS
- Anadys Pharmaceuticals to Report Third Quarter 2009 Financial Results
Oct 22, 2009 04:05 PM | ANDS
- Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Oct 20, 2009 04:05 PM | ANDS
- JMP Securities Healthcare Conference to Be Held in New York
Sep 29, 2009 05:30 PM | ACAD, ALNY, ALTH, ALXA, ANDS, ATHN
- Anadys Pharmaceuticals to present at the JMP Securities Healthcare Focus Conference
Sep 28, 2009 04:05 PM | ANDS
- Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
Sep 09, 2009 07:30 AM | ANDS
- Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Sep 03, 2009 07:02 PM | ANDS
- FDA Calendar Updates: Anadys, Merck, Schering-Plough
Jul 30, 2009 09:10 PM | ANDS, MRK, SGP
- OTC Select Announces Nasdaq Stock Watch
Jun 01, 2009 04:00 PM | AGEN, ANDS, CGRB, DVAX, EPEX
- Las Vegas Sands, Disney, UBS, Ford are big movers
Jul 31, 2009 06:13 PM | ANDS, F, LVS, PKI, SYNA, YRCW
- SAIC, KeyCorp, Textron, UAL are big movers
Jun 04, 2009 05:52 PM | ANDS, ANF, INTC, KEY, TXT, UAUA
- ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
Aug 11, 2009 07:30 AM | ANDS
- Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
Jul 30, 2009 04:10 PM | ANDS
- Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
Jul 30, 2009 04:06 PM | ANDS
- Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
Jul 23, 2009 04:07 PM | ANDS
- Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
Jun 04, 2009 09:55 AM | ANDS
- Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Jun 04, 2009 09:26 AM | ANDS
- Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Apr 23, 2009 04:06 PM | ANDS
- ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Apr 23, 2009 11:07 AM | ANDS
- Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
Apr 17, 2009 06:29 PM | ANDS
- Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference - Mar 31 2009 4:37PM
Mar 31, 2009 04:05 PM | ANDS
- Form 4 Holtzman Steven H For: Oct 06 (10K)
Oct 06, 2009 05:59 PM
- Form 4 WORLAND STEPHEN T For: Aug 18 (10K)
Aug 20, 2009 07:24 PM
- Form 4 Freddo James L For: Aug 18 (10K)
Aug 20, 2009 07:22 PM
- Form 4 REED ELIZABETH E For: Aug 18 (10K)
Aug 20, 2009 07:19 PM
- Form 4 Slover Peter T For: Aug 18 (10K)
Aug 20, 2009 07:17 PM
- Form 3 Slover Peter T For: Jul 01 (10K)
Jul 09, 2009 09:10 PM
- Form 4 XANTHOPOULOS KLEANTHIS For: May 29 (10K)
May 29, 2009 03:24 PM
- Form 4 SCANGOS GEORGE A For: May 29 (10K)
May 29, 2009 03:22 PM
- Form 4 ANADYS PHARMACEUTICALS For: May 29 Filed by: PAPADOPOULOS STELIOS (10K)
May 29, 2009 03:21 PM
- Form 4 Holtzman Steven H For: May 29 (10K)
May 29, 2009 03:20 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ANDS
|
Compare to S&P
|
| YTD |
24.36 %
|
8.41 %
|
| 4 Weeks |
-22.31 %
|
-23.13 %
|
| 12 Weeks |
-12.56 %
|
-14.73 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: 34.38 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
Sales Growth in Last Quarter: -0.01 %
|
|
